Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now early-phase tilt small index

Leptomeningeal Disease: early-phase trial registry

4 of 5 indexed Leptomeningeal Disease trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #3,391 of 28,707 conditions by registered trial count.

5 US clinical trials · 4 currently recruiting · #3,391 of 28,707 conditions by registered trial count

Leptomeningeal Disease: 5 US clinical trials tracked, 4 recruiting.

Leptomeningeal Disease is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is H. Lee Moffitt Cancer Center and Research Institute, running 2 of these trials.

Enrollment posture brief

Registry condition leptomeningeal-disease

OPEN 4 | RECR 80% | LATE 0 | EARLY 4 | RANK #3391 | SPON 2

Nearest open-share peer: Acute Leukemia of Ambiguous Lineage (80% recruiting · 10 trials)

Ablation80%ACL Reconstruction80%Leptomeningeal Disease (this)80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Leptomeningeal Disease

Leptomeningeal Disease lists 4 open slots (80% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Leptomeningeal Disease on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Leptomeningeal Disease is recruiting above its size-band peers.

    4 of 5 indexed trials (80%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Leptomeningeal Disease research.

    H. Lee Moffitt Cancer Center and Research Institute accounts for 2 of 5 trials (40%). 4 distinct sponsors appear on at least one study for this condition label.

  3. Most Leptomeningeal Disease trials plan to enrol fewer than 100 people.

    Median target enrolment is 21 among the 5 trials that report a genuine target (sentinel values excluded). 4 of those (80%) plan for fewer than 100 participants.

  4. Leptomeningeal Disease research is mostly interventional.

    4 interventional and 1 observational studies make up this index (80% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 22

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Named interventions

Most-linked intervention names on Leptomeningeal Disease records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

QBS72S Drug
1 trials
High-dose Methotrexate (8 gm/m2; HD-MTX) Drug
1 trials
Dendritic Cell Vaccine Biological
1 trials
Neurological Assessment Other
1 trials
Pertuzumab Drug
1 trials
Radiation Therapy Radiation
1 trials
Trastuzumab Drug
1 trials

US sites by state

Facility locations filed on Leptomeningeal Disease trials. A trial with sites in several states counts in each.

Florida 2 trials
Texas 1 trials
New York 1 trials
North Carolina 1 trials
Missouri 1 trials
Maryland 1 trials
Illinois 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Leptomeningeal Disease page

5 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leptomeningeal Disease condition card totals 5 registered trials; most-linked intervention QBS72S; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.